Dao-Jun Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dao-Jun Hu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Baoyan Shen
Shanghai Jiao Tong Univ, Chongming Branch, Sch Med, Dept Clin Lab,Xinhua Hosp, Shanghai, Peoples R China
1 shared publicationDaojun Hu
Shanghai Jiao Tong Univ, Chongming Branch, Sch Med, Dept Clin Lab,Xinhua Hosp, Shanghai, Peoples R China
1 shared publicationFeng Chen
Shanghai Jiao Tong Univ, Chongming Branch, Sch Med, Dept Clin Pathol,Xinhua Hosp, Shanghai, Peoples R China
1 shared publicationJianlin Ren
Shanghai Jiao Tong Univ, Chongming Branch, Sch Med, Dept Clin Pathol,Xinhua Hosp, Shanghai, Peoples R China
1 shared publicationLi Li
Department of Orthopedics, The Second People’ Hospital of Hefei, Hefei, Anhui, China
1 shared publication- Li Zhang
Department of Laboratory Medicine, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Chongming Branch, Shanghai, China
1 shared publication
Latest Publications
- 1 November 2020
- Vol. 50 (6) , 726-733
Altered Serum Annexin A2 Might Be a New Potential Diagnostic Biomarker in Human Colorectal Cancer
Objective. Annexin A2 is a calcium dependent phospholipid binding protein that is a biomarker in cancers. However, the value of serum Annexin A2 in the diagnosis of colorectal cancer (CRC) is not clear. This study aimed to investigate clinical utility of serum Annexin A2 as a potential biomarker for CRC. Methods. Annexin A2 was analyzed in 20 cases of CRC tissues and 20 controls of normal adjacent paired tissues. Serum Annexin A2 was calculated in 59 CRC patients and 44 healthy subjects. Receiver operating characteristic (ROC) curve and logistic regression were utilized to evaluate the diagnostic effectiveness and construct diagnostic model. Results. Annexin A2 in CRC tissues was slightly higher than in normal adjacent paired tissues (chi 2=6.0652, p<0.05). Serum Annexin A2 in CRC patients was significantly lower than in healthy controls (p<0.05). Besides, the levels of serum Annexin A2 were lower in patients with poor tumor differentiation than in well or moderate tumor differentiation (p=0.0111). ROC analysis indicated the diagnostic efficacy of serum Annexin A2 was better than carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA199) for CRC. Furthermore, joint detection of Annexin A2 and CEA had the maximum area under the ROC curve (AUC) in discriminating CRC from healthy controls (AUC 0.931, sensitivity 86.4%, specificity 84.7%, positive predictive value 87.9%, and negative predictive value 82.2%). Conclusions. Serum Annexin A2 may be a non-invasive and promising biomarker for the diagnosis of CRC, and the joint detection of Annexin A2 and CEA may have been favorable clinical applied value in the diagnosis of CRC.
- 1 November 2020
- Vol. 50 (6) , 726-733
Altered Serum Annexin A2 Might Be a New Potential Diagnostic Biomarker in Human Colorectal Cancer
Objective. Annexin A2 is a calcium dependent phospholipid binding protein that is a biomarker in cancers. However, the value of serum Annexin A2 in the diagnosis of colorectal cancer (CRC) is not clear. This study aimed to investigate clinical utility of serum Annexin A2 as a potential biomarker for CRC. Methods. Annexin A2 was analyzed in 20 cases of CRC tissues and 20 controls of normal adjacent paired tissues. Serum Annexin A2 was calculated in 59 CRC patients and 44 healthy subjects. Receiver operating characteristic (ROC) curve and logistic regression were utilized to evaluate the diagnostic effectiveness and construct diagnostic model. Results. Annexin A2 in CRC tissues was slightly higher than in normal adjacent paired tissues (chi 2=6.0652, p<0.05). Serum Annexin A2 in CRC patients was significantly lower than in healthy controls (p<0.05). Besides, the levels of serum Annexin A2 were lower in patients with poor tumor differentiation than in well or moderate tumor differentiation (p=0.0111). ROC analysis indicated the diagnostic efficacy of serum Annexin A2 was better than carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA199) for CRC. Furthermore, joint detection of Annexin A2 and CEA had the maximum area under the ROC curve (AUC) in discriminating CRC from healthy controls (AUC 0.931, sensitivity 86.4%, specificity 84.7%, positive predictive value 87.9%, and negative predictive value 82.2%). Conclusions. Serum Annexin A2 may be a non-invasive and promising biomarker for the diagnosis of CRC, and the joint detection of Annexin A2 and CEA may have been favorable clinical applied value in the diagnosis of CRC.
- Open Access
- 29 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 25204
A Mendelian Randomization Study of Plasma Homocysteine and Multiple Myeloma
Observational studies have demonstrated an association between elevated homocysteine (Hcy) level and risk of multiple myeloma (MM). However, it remains unclear whether this relationship is causal. We conducted a Mendelian randomization (MR) study to evaluate whether genetically increased Hcy level influences the risk of MM. We used the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism as an instrumental variable, which affects the plasma Hcy levels. Estimate of its effect on plasma Hcy level was based on a recent genome-wide meta-analysis of 44,147 individuals, while estimate of its effect on MM risk was obtained through meta-analysis of case-control studies with 2,092 cases and 4,954 controls. By combining these two estimates, we found that per one standard-deviation (SD) increase in natural log-transformed plasma Hcy levels conferred a 2.67-fold increase in risk for MM (95% confidence interval (CI): 1.12–6.38; P = 2.7 × 10−2). Our study suggests that elevated Hcy levels are causally associated with an increased risk of developing MM. Whether Hcy-lowering therapy can prevent MM merits further investigation in long-term randomized controlled trials (RCTs).
- 29 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 25204
Open AccessA Mendelian Randomization Study of Plasma Homocysteine and Multiple Myeloma
Observational studies have demonstrated an association between elevated homocysteine (Hcy) level and risk of multiple myeloma (MM). However, it remains unclear whether this relationship is causal. We conducted a Mendelian randomization (MR) study to evaluate whether genetically increased Hcy level influences the risk of MM. We used the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism as an instrumental variable, which affects the plasma Hcy levels. Estimate of its effect on plasma Hcy level was based on a recent genome-wide meta-analysis of 44,147 individuals, while estimate of its effect on MM risk was obtained through meta-analysis of case-control studies with 2,092 cases and 4,954 controls. By combining these two estimates, we found that per one standard-deviation (SD) increase in natural log-transformed plasma Hcy levels conferred a 2.67-fold increase in risk for MM (95% confidence interval (CI): 1.12–6.38; P = 2.7 × 10−2). Our study suggests that elevated Hcy levels are causally associated with an increased risk of developing MM. Whether Hcy-lowering therapy can prevent MM merits further investigation in long-term randomized controlled trials (RCTs).